Dr. Scott T. Tagawa

Dr. Scott T. Tagawa, MD, MS, is a nationally regarded medical oncologist, specializing in the treatment of genitourinary cancers including prostate, bladder, and testicular malignancies. He serves as Chief of the Solid Tumor Oncology Service at NewYork-Presbyterian/Weill Cornell Medical Center and holds the Richard A. Stratton Associate Professorship in Hematology and Oncology at Weill Cornell Medicine. Dr. Tagawa earned his medical degree from the University of Southern California School of Medicine, completed his internal medicine residency at UCLA Medical Center, and pursued fellowship training in hematology and medical oncology at Memorial Sloan Kettering Cancer Center. He is board-certified in Internal Medicine, Hematology, and Medical Oncology.

Dr. Tagawa is widely recognized for his expertise in the development of novel therapeutics for advanced prostate and urothelial cancers, including radiopharmaceuticals, antibody-drug conjugates, and targeted agents. He has led numerous early- and late-phase clinical trials and contributed significantly to advancing precision oncology approaches for metastatic disease. His research has been extensively published in high-impact peer-reviewed journals, and his work has helped inform treatment guidelines and regulatory approvals in the genitourinary oncology field.

In addition to his research and clinical leadership, Dr. Tagawa is a committed educator and mentor, training the next generation of oncologists through his work at Weill Cornell and collaborative clinical trial networks. He plays an active role in national research consortia and advisory boards, shaping the future of cancer therapy through innovation and multidisciplinary collaboration. Through his dedication to translational research, academic mentorship, and clinical excellence, Dr. Tagawa continues to elevate the standards of care for patients with genitourinary cancers.